NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 102.1 USD | +1.89% |
|
+4.97% | +1.12% |
| May. 10 | Novartis’ Scemblix Gets Third US FDA Breakthrough Therapy Designation | MT |
| May. 10 | Novartis Gets FDA Breakthrough Therapy Designation for Scemblix | DJ |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 684B | ||||||
| 568B | ||||||
| 361B | ||||||
| 329B | ||||||
| 284B |
